United Therapeutics Corporation is a biotechnology company focused on the development and commercialization of innovative therapies to treat various life-threatening medical conditions. The company was founded in 1996 by Martine Rothblatt, a prominent entrepreneur and advocate for advanced medical technologies. United Therapeutics is headquartered in Silver Spring, Maryland, USA.
The primary focus of United Therapeutics is on developing treatments for pulmonary arterial hypertension (PAH), a severe and potentially life-threatening condition characterized by high blood pressure in the arteries that supply blood to the lungs. The company's flagship product is Remodulin (treprostinil), an intravenous and subcutaneous drug used for the treatment of PAH. Additionally, they have other approved products, such as Tyvaso, Orenitram, and Adcirca, all targeting PAH treatment.
United Therapeutics is also actively involved in developing therapies for other medical conditions, including neuroblastoma, which is a rare form of cancer that primarily affects children. Furthermore, the company is engaged in research and development to explore the potential of regenerative medicine and organ transplantation through xenotransplantation, using pig organs for human transplantation.
The company's commitment to advancing medical science and developing therapies for rare and life-threatening diseases has garnered recognition and awards within the biotechnology and healthcare industries. Through continuous research and development efforts, United Therapeutics aims to improve the lives of patients suffering from challenging medical conditions and contribute to the advancement of medical science.